Human-first heart development
Ronald A Li, CEO and Co-Founder at Medera, explores how human-centred preclinical models are transforming cardiovascular drug development.
When we published our previous article in Drug Discovery World last September, we argued that human-based mini-Heart technology could fundamentally reshape cardiovascular drug development by reducing reliance on animal models and improving translational predictability. That argument, grounded in strong science, ultimately required patient validation.
Today, that validation is emerging at scale.
Over the past year, three FDA-cleared cardiac gene therapy programmes—MUSIC-HFrEF, MUSIC-HFpEF, and MUSIC-DMD-CM—have reached important clinical milestones. Together, they suggest that development strategies rooted in human biology from the earliest stages can enhance safety, improve development efficiency, and reduce late-stage failure.
This progress arrives at a pivotal moment for the gene therapy field. Recent safety setbacks have heightened regulatory scrutiny and investor caution. These challenges have underscored an essential reality: in gene therapy, safety is not simply a clinical priority—it is the foundation of commercial viability and long-term platform credibility.
Clinical validation at scale
The most significant early validation has emerged from the MUSIC-HFpEF Phase I/IIa trial. Interim data presented as a Late-Breaking Clinical Trial at the American Heart Association Scientific Sessions in November 2025 marked the first clinical report of a first-in-human gene therapy candidate in heart failure with preserved ejection fraction (HFpEF).
Across our SRD clinical programmes, 21 patients have been dosed without immunosuppressive therapy. No clinically significant immune reactions, liver enzyme abnormalities, or serious gene therapy-related adverse reactions have been observed, and no safety-related trial interruptions have occurred over at least 12 months of follow-up.
In the MUSIC-HFpEF low-dose cohort, improvements were observed in New York Heart Association functional class, stabilisation and improvement in pulmonary capillary wedge pressure, and favourable trends in biomarkers including NT-proBNP and high-sensitivity troponin. Taken together, these findings indicate consistent physiologic, functional, and biomarker signals rather than isolated statistical fluctuations. While longer-term outcomes remain essential, the coherence of these early data points is encouraging.
HFpEF represents approximately half of global heart failure cases, affecting an estimated 32 million patients worldwide. Current therapies primarily address symptoms rather than underlying disease mechanisms. Our investigational candidate, SRD-002, was designed to target molecular drivers of diastolic dysfunction, myocardial stiffness, and impaired calcium handling.
Importantly, its development was guided by a human HFpEF disease model co-developed with AstraZeneca. The resulting clinical data to date align closely with these early predictions, with no unexpected safety liabilities observed.
In January 2026, enrollment of the high-dose cohort in MUSIC-HFpEF was completed. All five patients in Cohort B received a 50% higher therapeutic dose, yet remained approximately 100-fold below levels typically required for systemic IV administration. No immunosuppression was required.
More mature efficacy data from this cohort are still being analysed and will be reported in due course. Early internal reviews suggest further encouraging trends, but formal disclosure awaits full validation and regulatory alignment.
Parallel progress has been made in MUSIC-HFrEF. Following review of all Phase Ib data, the independent Data and Safety Monitoring Board recommended advancement to Phase II. A randomised, double-blind, placebo-controlled study of 50 patients is now enrolling.
Across the heart failure with reduced ejection fraction (HFrEF) and HFpEF programmes, primary translational decisions—including dose optimisation, biological validation, and potency assessment of clinical-grade gene therapy products—have been driven by human mini-Heart models, supporting FDA Investigational New Drug (IND) clearance and Fast Track designation.
Why safety defines competitive success
Gene therapy differs fundamentally from conventional pharmacology. Whereas small-molecule safety signals may sometimes be mitigated through dose adjustment, a single major adverse event in gene therapy can trigger clinical holds, platform-wide reassessment, and long-term reputational damage.
Recent industry experiences illustrate this vulnerability. When safety concerns emerge, they often extend beyond individual assets to entire vector systems, delivery approaches, and manufacturing platforms.
A central contributor to risk has been systemic delivery of high viral doses, frequently accompanied by immunosuppression and off-target organ exposure, increasing the probability of hepatic toxicity, immune complications, and manufacturing constraints.
Earlier cardiac gene therapy programmes helped illuminate these structural limitations. The field has learned from those experiences, creating an opportunity for more targeted, biology-driven approaches.
By prioritising localised delivery and human-centered development from inception, our programmes were designed to address safety challenges proactively rather than reactively. Regular formal interactions with the FDA, including multiple Type B meetings, have reinforced regulatory confidence in the translational framework.
Competitive advantage through targeted delivery and platform design
Our therapeutic doses—optimised through human-based modeling—are approximately 100-fold lower than those required for systemic IV infusion. This reduction is achieved through an outpatient, minimally invasive intracoronary delivery method that concentrates vector exposure within cardiac tissue.
This design reflects a broader third-generation approach to cardiac gene therapy.
Earlier generations were constrained by vector purity (with empty capsid ratios approaching 70%, compared with approximately 1% today), manufacturing yield, and delivery efficiency. Advances in process development now enable more precise dosing, improved consistency, and tighter quality control.
Medera’s current platform integrates these advances with localised delivery, allowing modern manufacturing capabilities to be fully leveraged at clinically meaningful doses. The result is improved safety margins, more predictable pharmacodynamics, and enhanced commercial scalability.
Lower doses reduce systemic toxicity risk and simplify clinical protocols. Patients typically require only brief inpatient observation, avoiding prolonged hospitalisation and immunosuppression. Clinical trial execution becomes more efficient, and patient burden is reduced.
Manufacturing scalability improves concurrently. Lower per-patient vector requirements increase production capacity and reduce cost of goods. For organ-specific diseases such as cardiomyopathy, targeted delivery is not merely a technical refinement—it is a prerequisite for sustainable commercialisation.
Today, Medera remains the only company conducting intracoronary adeno-associated virus (AAV) gene therapy trials for both HFpEF and HFrEF, enabling this integrated dose-sparing and manufacturing strategy.
Economic implications of human-first development
Historically, nearly 90% of drug candidates that succeed in animal testing fail in human trials, with development costs frequently exceeding $1 billion per approved therapy.
Human-based screening alters this trajectory.
In our programmes, early human tissue modeling eliminated multiple non-viable development paths before clinical entry. Vector constructs, promoters, and dosing regimens were refined prior to IND submission, reducing downstream failure risk.
The economic effects compound over time: fewer late-stage failures, shorter development timelines, and more predictable regulatory pathways. Combined, these factors create a sustainable framework for innovation in complex cardiovascular diseases.
Regulatory alignment and the role of NAMs
In parallel with scientific progress, regulatory agencies are increasingly emphasising the role of New Approach Methodologies (NAMs) in biomedical research and development. Both the FDA and NIH have articulated formal initiatives encouraging the adoption of human-relevant models to improve translational reliability and reduce unnecessary animal use.
These policy developments reflect a growing consensus that traditional preclinical paradigms require modernisation.
Medera has been engaged in cardiac NAM development since the early 2000s, evolving through collaboration with regulatory, industrial, and clinical partners. Members of our leadership team have contributed to national initiatives such as the FDA’s Comprehensive In Vitro Proarrhythmia Assay (CiPA) programme, which aims to improve human-relevant cardiac safety assessment.
Our experience underscores that regulatory acceptance of NAMs is strongest when these models are embedded within rigorous development frameworks and supported by clinical validation. Translation, rather than substitution alone, remains the ultimate benchmark.
The path forward
Six months ago, we presented a scientific case for integrating human-based models into cardiovascular development. Today, that framework is being tested in active clinical programmes.
Three FDA-cleared trials are enrolling. Twenty-one patients have been treated without gene therapy–related adverse reactions. Early efficacy signals are emerging in conditions historically resistant to intervention.
Not every early signal will translate, and long-term outcomes remain essential. Nonetheless, the convergence of safety, mechanistic coherence, manufacturing maturity, and regulatory engagement suggests that human-centered development can materially improve the probability of success.
For drug developers facing increasing pressure to de-risk cardiovascular pipelines while accelerating timelines, the question is no longer whether human-based models will play a central role. The question is how quickly they can be integrated into existing discovery and development systems.
Those who adapt early will be positioned to deliver safer, more effective, and more economically viable therapies. Gene therapy remains under intense scrutiny—and rightly so. That scrutiny reflects maturation of the field.
By reducing dependence on animal extrapolation while strengthening predictive power through human biology, it is possible to advance both scientific rigor and ethical responsibility. For millions of patients living with incurable cardiovascular diseases, that shift cannot come too soon.
About the author
Dr Ronald A Li is CEO and Co-Founder of Medera and a recognised leader in cardiac electrophysiology, human heart cell and tissue engineering, and cardiac gene and cell therapy. Formerly an Assistant, Associate, and Full Professor and Center Director at Johns Hopkins, UC Davis, Mount Sinai, and Karolinska Institutet, he has authored over 200 peer-reviewed publications and leads Medera’s clinical and translational strategy.
From DDW Volume 27 – Issue 2, Spring 2026 – Read the digital issue here
